The right patient, at the right time: How to optimize outcomes for HCC patients with liver imaging? 

Over 90% of HCC cases occur in the setting of chronic liver disease. The incidence of MASLD (metabolic dysfunction–associated fatty liver disease)-related HCC is projected to increase dramatically by 2030. Therefore, healthcare providers seek ways to better stratify patients with liver diseases to detect HCC earlier and ultimately improve outcomes. 
Watch now the Liver Cancer Symposium and get insights on the key topics: 

• Early detection of liver diseases and HCC has become a significant topic. Join Prof. Paul Sidhu in this session and learn how Ultrasound has proven cost-effective, easy to access and efficient in the surveillance of liver diseases from fatty liver to HCC detection and characterization. 
• How did abbreviated MRI protocols became a hot topic in liver imaging recently? In this session, Prof. Jeong Hee Yoon will discuss the potential role and practical considerations of abbreviated MRI as an alternative HCC surveillance modality.
• PCD-CT represents the most recent generational advance in CT technology and has the potential to reduce image noise, improve spatial resolution, improved contrast resolution, and provide multispectral capability, all of which may be achieved with an overall decrease in radiation dose.

Compared with energy-integrating detector (EID) CT, PCD-CT substantially improves focal liver lesion detection, especially at low radiation dose while maintaining diagnostic accuracy.